{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:00:08Z","timestamp":1784973608403,"version":"3.55.0"},"reference-count":42,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2008,6,18]],"date-time":"2008-06-18T00:00:00Z","timestamp":1213747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:p>Abstract<\/jats:p>\n                  <jats:p>Schizophrenia is one of the most expensive illnesses. Antipsychotics are an essential component of the acute and preventative treatment of this illness, and long-term treatment is necessary to decrease the risk of psychotic relapse. The efficacy and tolerability of flupentixol was evaluated in a post-marketing surveillance study (PMS) in schizophrenic patients receiving long-term treatment in routine clinical practice. Psychiatrists in office practice treated patients for approximately 10\u00a0weeks, with a subsequent follow-up period of up to 18\u00a0months. We here report on the follow-up period in 128 patients. The benefit for schizophrenic patients increased with the treatment duration of flupentixol as documented by the Clinical Global Impression (CGI). Subjective quality of life improved during the first study period, and this remained stable in the follow-up period. No increase in body weight was observed during the study. The relapse rate was much lower than in other studies. Anticholinergic medication was necessary for 22.7% of the patients at any time. More than 70% of the psychiatrists involved evaluated the treatment as very good or good. The results of this study suggest that flupentixol is a potent and safe antipsychotic for the long-term treatment of schizophrenia in routine clinical practice.<\/jats:p>","DOI":"10.1177\/0269881108091879","type":"journal-article","created":{"date-parts":[[2008,6,18]],"date-time":"2008-06-18T20:34:22Z","timestamp":1213821262000},"page":"805-813","source":"Crossref","is-referenced-by-count":7,"title":["Long-term treatment with flupentixol results of a post-marketing surveillance study"],"prefix":"10.1177","volume":"23","author":[{"given":"T","family":"Messer","sequence":"first","affiliation":[{"name":"Clinic for Psychiatry and Psychotherapy, Regional Hospital Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Glaser","sequence":"additional","affiliation":[{"name":"Bayer Vital GmbH, Leverkusen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Landen","sequence":"additional","affiliation":[{"name":"Bayer Vital GmbH, Leverkusen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Schmauss","sequence":"additional","affiliation":[{"name":"Clinic for Psychiatry and Psychotherapy, Regional Hospital Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2008,6,18]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.4.290"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2005.01198.x"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(03)00061-0"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000295925"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a006928"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1016982"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa002028"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.6.553"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.1.103"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-93700-2_4"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-832684"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199501005-00004"},{"key":"atypb13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/j.1875-9114.1991.tb02660.x","volume":"11","author":"Gruber AJ","year":"1991","journal-title":"Pharmacotherapy"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-003-1620-4"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.2.185"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1159\/000068874"},{"key":"atypb17","first-page":"S35","volume":"53","author":"Ito C","year":"1999","journal-title":"Psychiatry Clin.Neurosci"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.epirev.a036164"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.10.1079"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1614.1999.00639.x"},{"key":"atypb21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-2004-818386","volume":"72","author":"Kuhn KU","year":"2004","journal-title":"Fortschr Neurol Psychiatr"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.7.1209"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.8.1396"},{"key":"atypb25","unstructured":"Lohse A\u2004 Lorenzen B\u2004 M\u00fcller-Oerlinghausen, b (2004) \"Verordnung von Psychopharmaka.\" In: Schwabe, W, Pfaffrath, A, (eds), Arzneiverordnungsreport. Heidelberg: Springer; 2005."},{"key":"atypb26","unstructured":"Messer T\u2004 Gaxiola D\u2004 Schmauss M\u2004 (2006) \"Educational level, employment situation and housing situation of psychiatric in-patients on admission.\" Psychiatr Prax 1."},{"key":"atypb27","unstructured":"Messer T\u2004 Glaser T\u2004 Schmauss M\u2004 (2003) Therapeutischer stellenwert von flupentixol und flupentixoldecanoat. Psychopharmakotherapie 4: 141\u2013150."},{"key":"atypb28","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-2002-34655","volume":"29","author":"Muller P","year":"2002","journal-title":"Psychiatr Prax"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00166-3"},{"key":"atypb30","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2000.00016.x"},{"key":"atypb31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1055\/s-2007-995283","volume":"66","author":"Pach J","year":"1998","journal-title":"Fortschr Neurol Psychiatr"},{"key":"atypb32","unstructured":"Philipp M\u2004 Lesch OM\u2004 Walter H\u2004 Patras L\u2004 Kurtz G\u2004 Schmauss M\u2004 (2002) Wirksamkeit von Flupentixol vs. Risperidon auf die Negativsymptomatik schizophrener Patienten - Ergebnisse einer multizentrischen doppelblinden Non-Inferiorit\u00e4tsstudie. Psychopharmakotherapie 2: 67\u201374."},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.2.266"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2007.02.014"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.1.79"},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199910000-00016"},{"key":"atypb37","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145703004012"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.54.1.55"},{"key":"atypb39","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1055\/s-2004-828463","volume":"31","author":"Vogel M","year":"2004","journal-title":"Psychiatr Prax"},{"key":"atypb40","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.4.300"},{"key":"atypb41","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700048091"},{"key":"atypb42","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.04.012"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881108091879","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881108091879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:05:21Z","timestamp":1777507521000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881108091879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,18]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1177\/0269881108091879"],"URL":"https:\/\/doi.org\/10.1177\/0269881108091879","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,18]]}}}